Herbal Medicine Applications for Polycystic Ovarian Syndrome

Edited by
Younis Ahmad Hajam
Rajesh Kumar
D. R. Thakur
and Seema Rai

CRC Press
Taylor & Francis Group

Designed cover image: © Shutterstock

First edition published 2024
by CRC Press
2385 NW Executive Center Drive, Suite 320, Boca Raton FL 33431

and by CRC Press
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN

CRC Press is an imprint of Taylor & Francis Group, LLC

ISBN: 9781032383767 (hbk)
ISBN: 9781032383712 (pbk)
ISBN: 9781003344728 (ebk)

DOI: 10.1201/9781003344728

Typeset in Times
by codeMantra

Contents

1 Polycystic Ovarian Syndrome (PCOS)

Signs, Symptoms, Epidemiology, Environmental Stress, Management Strategies and Current Therapies

Younis Ahmad Hajam
Sant Baba Bhag Singh University

Rajesh Kumar
Himachal Pradesh University

Neelam
Sant Baba Bhag Singh University

D. R. Thakur
Himachal Pradesh University

Seema Rai
Guru Ghasidas Vishwavidayalaya (A Central University)

CONTENTS

DOI: 10.1201/9781003344728-1

1.1 INTRODUCTION

According to the World Health Organization, fitness isn't always the absence of sickness or infirmity; however, it involves a balance between physical, mental, and social well-being. Although this definition of fitness might also appear unrealistic, nowhere it greater appropriates and is justified than in subject of reproductive fitness. Because of the energetic contribution of females, their fitness makes a society fit and healthy (Fathalla, 1997). Woman who finds it hard to conceive cannot be taken into consideration as healthy and effective because of the stress elevation inside the blood and exposure of fetus to an ordinary biophysical profile.

According to this constructive expertise, the reproductive fitness of a country is decided on the basis of physical, mental, and social well-being, as well as the absence of sickness or soreness during the reproductive technique. Reproductive fitness consists of folks who can reproduce, manage fertility, and attain and revel in intimate relationships with the absence of infection or sickness. It additionally indicates that the delivery of a newborn and its survival, healthful boom, and improvement are going well. Sexual fitness of females is utmost important to have a good reproductive system, which makes their lives comfortable, increases the tendency of decision-making, and facilitates while planning for pregnancy.

Women's reproductive and sexual fitness issues, together with menstruation, fertility, delivery management, pregnancy, sexually transmitted infections, menopause, endometriosis, and polycystic ovarian syndrome (PCOS), are associated with distinct life stages. Concerns related to the reproductive fitness in women consist of mutilations in reproductive organs or organs that are managed with the aid of using the estrogen in females. Several illnesses related to the reproductive device in women are curable, while a few are chronic or are deadly. Many forms of illnesses or problems disturb fertility while sexual assaults, social sites, pollutants, and exquisite quantity of endocrine toxicants increase instances of hormonal conflicts.

All such unusual reproductive and hormonal irregularities, along with endometriosis, may cause absence/untimely periods, PCOS, fibroids, infertility, most cancers in ovary, miscarriage, ectopic pregnancy, untimely delivery, etc. (Akhter et al., 2017; Rai et al., 2015). PCOS is a collection of illnesses, which affects women's reproductive system, especially those in older age. PCOS is not an unusual endocrine situation that affects women of reproductive age. It is an underrecognized, underdiagnosed, and understudied infection that disproportionately influences women worldwide, particularly in underdeveloped nations. Stein and Leventhal first recognized women with PCOS in 1935 (Azziz and Adashi, 2016). Some researchers also call it Stein and Leventhal syndrome. In preliminary stages, PCOS in women continues to be undiagnosed. Therefore, the long-term hazards associated with PCOS are diabetes

mellitus (T2DM) and cardiovascular disorders. PCOS is an endocrine disorder in addition to reproductive diseases accounting for its incidence among 5%–25% (Gill et al., 2012) in female population. Women of reproductive age had oligoovulation (O), hyperandrogenism (H), and polycystic ovaries (revised 2003 consensus on diagnostic standards, 2004). PCOS is principally H in addition to O at some stages in the reproductive age, leading to infertility (Rosenfield and Ehrmann, 2016) and medical or metabolic disorders (Detti et al., 2015). The characteristics of PCOS are depicted in Figure 1.1.

Women who've metabolic and reproductive troubles are much more likely to become infertile and develop endometrial cancer; hence, early detection and powerful remedies are essential for its control (Fearnley et al., 2010). Currently, there is powerful proof linking PCOS with obesity, insulin resistance, and a better threat of growing noninsulin-based T2DM (Lee et al., 2009). PCOS is moreover responsible for causing specific continual health troubles, metabolic troubles, and intellectual troubles, such as cardiovascular diseases, horrible self-esteem, venous thromboembolism, and anxiety (Bird et al., 2013).

The situation referred to as PCOS alters the quantities of hormones in women. More male hormones are produced than that is normal by means of PCOS-affected women. Due to the imbalance, menstruation may not be in time and may additionally contribute to baldness, frame hair, and facial hair (Basheer et al., 2018; Rani et al., 2022).



FIGURE 1.1 The PCOS-induced complications such as hormonal, hirsutism, hyperandrogenism, anovulation, acanthosis nigricans oxidative stress, and histological changes.

1.1.1 Characteristics

i. One common hormonal situation affecting girls of childbearing age is PCOS.
ii. Women with PCOS may also additionally have shorter or longer menstrual cycles because of multiplied testosterone levels.
iii. The ovaries may also additionally collect a few fluids (follicles) and no longer launch eggs regularly.
iv. Commonly in all cases, females with PCOS may have abnormal menstrual cycles and an additional accumulation of male hormones (androgen).
v. The situation is known as, after the invention, an enlarged ovary containing many small cysts (polycystic ovaries).
vi. Most women with PCOS have polycystic ovaries.

1.1.2 Signs and Symptoms

Some signs and symptoms of PCOS may frequently be seen throughout puberty. Sometimes, PCOS at later stages may develop sizable weight gain. The symptoms and signs of PCOS vary from individual to individual.

Irregular intervals: Infrequent, abnormal, or lengthy menstrual cycles are the signs and symptoms of PCOS. For example, one can have fewer than nine intervals a year, more than 35 days among intervals, and really heavy intervals.

Excess androgen: Elevated testosterone degrees may exhibit bodily symptoms, which include immoderate facial and frame hair (hirsutism) and occasionally extreme pimples and hair loss.

Polycystic ovary: The ovaries might also additionally develop and incorporate follicles surrounding the egg. As a result, the ovaries might also additionally feature irregularly.

Type-2 diabetes: It has additionally been pronounced that females with PCOS have a bourgeoned danger of growing T2DM.

1.2 HISTORY OF PCOS

PCOS mainly occurs due to misbalancing of sex hormones and leads to the formation of cysts in the antral follicles of female ovaries. A cyst is formed of fluid-filled sacs enclosing the egg. The changing of egg into a cyst is defined as functional cyst, which further prevents ovulation. The process of ovulation gets suppressed, which subsequently disturbs the menstrual cycle and leads to amenorrhea. When multiple cysts are formed in the ovarian follicles because of imbalances in hormones, then it is termed as PCOS. Due to the fluid filled in the cysts, most of the cysts may be as big as 10 mm large, and the ovary size elevates up to 10 cm wide. The process of fertilization and conception is inhibited due to the absence of ovulation and menstrual cycle, thus pregnancy becomes complicated (Sirmans and Pate, 2014). During implantation, there is elevation in abortion and birth risks. Because of this, eclampsia and

the small-for-gestational-age babies can occur. PCOS also causes pregnancy-related problems such as gestational diabetes and hypertension (Homburg, 2009). Usually, support to the growing follicles is provided by theca cells in the formation of mature oocytes (Young and McNeilly, 2010). However, theca cells in patients with PCOS respond agitatedly to the stimulatory effects of insulin; thus, they multiply and cause hypertricosis. The androgen ability elevates in the ovarian theca cells because of insulin resistance, aggravating PCOS (Wang et al., 2009). The increased sensitivity of theca cells toward the stimulation of luteinizing hormone (LH) and follicle stimulating hormone (FSH) helps to androgenism in PCOS. The key feature that is responsible for PCOS is the distressed secretion of the pulsatile gonadotropin-releasing hormone (GnRH) from hypothalamus (Tsutsumi and Webster, 2009). GnRHs give signals to pituitary glands to secrete gonadotropins. Gonadotropins are very important for the two phases (follicular and ovulatory) of the menstrual cycle. In polycystic ovarian condition, as gonadotropins are present in very less amount, the formation of egg does not take place or is unable to liberate from the follicle. Therefore, the menstrual cycle is disturbed and amenorrhea occurs. Amenorrhea may be classified into two categories: primary and secondary. While primary amenorrhea is a condition in which menarche does not take place because of the genetic or anatomical reasons, whereas secondary amenorrhea or hypothalamic amenorrhea is a condition in which menstrual cycle is absent for three- or more repeated months (Klein and Poth, 2013). The activity of GnRH is blocked due to the presence of increased amounts of lactotrophic hormone, which is a peptide hormone (Marques et al., 2018).

Polycystic ovarian circumstance likewise takes place because of the extra quantity of androgen secretion by the interior ovary. Various intrinsic elements such as altered steroidogenesis occur in the outer spheres of the ovary. These elements encompass hyperinsulinemia,inflicting intense manufacturing of the male hormone, i.e., androgen. Women with PCOS have higher risk of developing follicles in comparison to the regular control. The family members among the paracrine, endocrine, and apocrine elements aren't clean and chargeable for the maturation of follicles and most of these can make a contribution to dysregulation of ovary in PCOS. The improvement of primordial follicles takes place in the course of the maturation of follicles and includes oocytes arrested at meiotic segment enclosed through pregranulosa cells. Ovaries are relatively inactive until the start of puberty. The variations inside the morphology of follicles and increased ability are there within the ovarian tissues received from the women of prepubertal and early puberty. Particularly, excessive quantity of nondeveloping follicles is found in prepubertal ovaries compared with pubertal ovaries (Anderson et al., 2014). Follicle density is the only element which has appeared (Gaytan et al., 2015). After the activation from the inactivation pool, the initial increase of follicles until the astral level is gonadotropin-independent. Ovarian granulosa cells secrete a glycoprotein known as antimullerian hormone (AMH) which prevents the recruitment of follicles and suggests follicular reserve. Contrary to mice, AMH prevents the increase of prenatal follicle and the maturation of follicle. In the ovaries of nonhuman primates compared with that in mice or rats, it can be determined that AMH leads in the increase of prenatal follicles to the astral level (Xu et al., 2016). Peak concentrations of AMHs are determined in follicles. The expression of AMH is suppressed through estradiol (Dumont et al., 2018).

Notwithstanding preceding statements that androgens negatively affect follicles, the synthesis of androgen takes place in prenatal follicle, and the increase of prenatal and follicles promoted through theca cells set off the expression of granulosa mobileular FSH receptor in early antral follicles (Franks and Hardy, 2018). Androgens aid the expression of aromatase enzyme and, eventually, granulosa cells additionally aid the expression of LH/chorionic gonadotropin receptor (LHCGR). As the maturation of follicles takes place, androgen seems to save the affected women from proliferation and aid mobileular death. This biphasic movement of androgen becomes first to be showed in a nonhistone protein, the marmoset (nonhuman primates); the movement of FSH is extended through androgens in small follicles, however in large follicles an inhibitory effect is confirmed (Laird et al., 2017). Androgen receptors (ARs) mediate the moves of androgens which can be expressed in theca cells of ovary, granulosa cells, oocytes, and stromal cells (Sen and Hammes, 2010). The gene expression of ARs takes place in small follicles (6 mm in diameter) and decreases in antral and preovulatory follicles (Jeppesen et al., 2012). Classically, the single-most effective dominant follicle is taken into consideration (Kristensen et al., 2018). Pituitary FSH decreases due to the bad remarks by growing the secretion of estrogen. The secretion of principal FSH reduces due to the bad remarks. The dominant follicle compensates for this lack of stimulation of FSH through expanded expression of LHCGR and will increase responsiveness to LH stimulation. Secondary follicles undergo atresia, mainly because of relative deficiency of FSH and addition of the male hormone, i.e., androgen. Upon getting excellent attention of estradiol, neuroendocrine mechanisms prompt the LH surge to set off ovulation. The ovarian stroma offers a structural framework underneath regular situations experiencing dynamic changes to hold the follicular increase, although the ovarian stroma from women having PCOS has a tendency to be highly rigid. Abnormal increase in the course of the early levels of follicular increase probably contributes to the ovarian characters of PCOS (Franks and Hardy, 2018).

1.3 PATHOGENESIS OF PCOS

The complex pathophysiology of PCOS has remained an understudied condition in the past. There are numerous hypothesized pathways, a number of which contain interactions among genes, hormones, and environmental stresses.

1.3.1 HORMONES

Gonadotropins, inclusive of the hormones LH and FSH, in addition to estrogen, progesterone, and testosterone, are vital in the pathophysiology of PCOS. In a great populace of females with PCOS, the range of LH and FSH increases and decreases, respectively (Raju et al., 2013; Saadia, 2020). The LH/FSH ratio increases due to it. The incidence of an excessive LH/FSH ratio sometimes does not take place in PCOS-infected females with ordinary weight and mass index, and it has partial correlation with BMI as well. The upward push in LH is defined through a boom inside the pulse frequency of hypothalamic GnRH. LH receptor-sporting theca cells of the ovaries are inspired to supply testosterone due to the upward push in LH.

1.3.2 Environmental Stressors

Obesity and prenatal publicity to androgens have been diagnosed as the important causal variables. Multiple genetic variables make a contribution to PCOS susceptibility, and the syndrome in the presence of a specific environment. It is thought that immoderate maternal androgen publicity at some point of being pregnant performs a big position in improvement of PCOS in fetuses. Moreover, oxidative pressure is another thing that supplies upward thrust to numerous issues, consisting of the PCOS situation. Antioxidants are not explained in detail in nutritional dietary supplements nowadays. This has brought about an alternate in favor of the usage of natural and ayurvedic products. The majority of bioactive additives observed in plants/flora have the capability to deal with issues such as PCOS (Figure 1.2).

1.3.3 Genetic Factors

There is proof of a genetic thing primarily based on the presence of familial clustering (Diamanti-Kandarakis et al., 2006). Genetically, same twins had better concordance of PCOS than nonsame twins, in accordance to analyze primarily based on dual data (Vink et al., 2006). The mode of inheritance of PCOS remains unknown, and no longer seems to rely upon genes worried within the manufacture and metabolism of testosterone and insulin (Jones, 2008). The role of genetic alterations in the PCOS-induced psychological issues has been mentioned in Figure 1.3.

1.4 RISK FACTORS OF PCOS

There are different factors that are accountable in inflicting PCOS along with genetic, way of life changes, and their combos which can reason PCOS. Thyroid dysfunctioning, hyperprolactinemia, androgen-secreting tumors, Cushing's syndrome, and congenital adrenal hyperplasia can confine pathogenesis of PCOS. The publicity to chemical



FIGURE 1.2 The effect of modulated HPO axis on the hormonal circuit.



FIGURE 1.3 The role of genetic alteration in the development of psychological issues and menstrual disturbances.



FIGURE 1.4 The effect of stress and obesity on the hypothalamus, pituitary gland, and adrenal cortex and their role in depression.

compounds has additionally been chargeable for the pathogenesis of PCOS. One can uncover chemical compounds by way of means of some of the methods such as accidental (pesticides, vehicles, commercial pollution, etc.) or cosmetics, floor cleansing agents, chemical therapeutics, etc., which are well known in current times. Various nonpublic care merchandise such as deodorants, sunscreens, hair dyes, etc. are the most important reasons at the back of the growing incidents of PCOS. Most of the consumers are unaware that these so-known as harmless hygiene merchandise are endocrine disruptors. These nonpublic care merchandises include numerous chemical compounds together with phthalates, parabens, isopropanol, glutaraldehyde, benzophenones, turpentine oil, and metals such as nickel sulfate, cobalt chloride, etc. (Yang et al., 2017). Various chemical compounds, along with bisphenols A, are also found in packaged and canned food that can be one of the main reasons for numerous reproductive problems together with PCOS (Konieczna et al., 2015). PCOS also causes depression due to stress and obesity by altering the hypothalamic-pituitary adrenal axis (Figure 1.4).

1.5 PREVALENCE OF PCOS

The European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) in 2003, additionally referred to as the Rotterdam standards, and the Androgen Excess Society and PCOS Society (AE-PCOS) in 2006 have been the primary standards for the analysis of PCOS at a worldwide convention held by the NIH in 1990 (Garad et al., 2011). Every diagnostic criterion has precise scientific and biochemical evaluation that decides whether PCOS is present or absent (Okoroh et al., 2012a). According to the NIH's 1990 standards, PCOS may be identified in sufferers who showcase O and H signs and symptoms. The want for greater complete diagnostic standards brought about the improvement of the Rotterdam standards from 2003 (Okoroh et al., 2012b). The Rotterdam's standards are carried out if the affected person reveals signs and symptoms of O, H, and polycystic ovaries (Azziz et al., 2009). The AE-PCOS standards, which have been released in 2006, are carried out if people show symptoms and symptoms of H with scientific or laboratory evidence (Azziz et al., 2009). In 2012, a workshop was held to increase new diagnostic standards. The following phenotypes have been advised during the workshop:

I. Excessive androgen or ovulatory dysfunction.
II. Polycystic ovarian morphology or androgen excess.
III. Polycystic ovarian morphology or ovarian ovulatory failure.
IV. Polycystic ovarian morphology, excess androgen, or ovarian dysfunction (Johnson et al., 2012).

Currently during 2018, International Guidelines for Polycystic Ovarian Syndrome approve the Rotterdam standards with a few cautions. An ultrasound remains encouraged for phenotyping, although it isn't always vital for analysis if the affected person has abnormal menstrual durations or H. Teenagers should not go through ultrasounds (Wolf et al., 2018). PCOS is a medical disease and studies have proven that there's no unmarried set of standards for the analysis of polycystic ovaries (Meurer et al., 2006). According to the diagnostic standards employed, the superiority of PCOS stages from 4% to 10% and has an annual value greater than $4.3 billion (Goodarzi and Azziz, 2006 and Azziz et al., 2005).

1.6 EFFECT OF THE DIAGNOSTIC CRITERIA ON PREVALENCE

The incidence of PCOS is distinctly laid low with the modifications made within the diagnostic standards. By combining all the three standards, occurrence turned into as little as 1.6% (Okoroh et al., 2012) and as excessive as 18% (March et al., 2010) in comparable Caucasian populations using Rotterdam standards (Lim et al., 2013). It has been mentioned that 50%–75% of girls with polycystic ovaries are unaware that they have been affected by PCOS (Futterweit, 1999). A retrospective study evaluated a set of 204 age-matched girls who were suspected to have polycystic ovary to determine the incidence primarily based on the diagnostic standards (Amato et al., 2008). It has been reported in step with NIH the superiority of PCOS: Within the diagnosed populace the superiority turned into 51%, in step with Rotterdam's standards the

superiority turned into 83%, in step with AE-PCOS it turned into 70.6%, and below all the three standards the superiority turned into simplest 49% (Amato et al., 2008). Findings revealed that there's a distinction in the superiority, frequency, and severity of signs and symptoms as well. The Rotterdam standards were used to evaluate all the instances, after which it was redefined and a prognosis was made to the use of the standards of NIH to decide the occurrence of polycystic ovaries in step with the two unique definitions (Broekmans et al., 2006). Under the Rotterdam's standards, there has been an improved price of immoderate weight, insulin sensitivity, and the prognosis of polycystic ovaries itself (Broekmans et al., 2006). The appropriate businesses and the identical topics have been used on this look to evaluate an actual instance of the variations which could take location among the standards. The incidences of the Rotterdam and AE-PCOS whilst as compared to the NIH standards turned almost two times when assessed for identical topics (March et al., 2010). The loss of uniformity and transparency among the diagnostic standards affect the comparison and the consistency of all medical remedies and studies related to polycystic ovaries. Yildiz et al. (2012) reported that the incidence is substantially laid low with diagnostic standards. Over-prognosis is probably there due to the addition of extra phenotypes in diagnostic standards, and the brand-new addition of nonhyperandrogenic phenotype below the Rotterdam's standards (Copp et al., 2017). Women, who aren't having hyperandrogenism, have been identified to have much less continual relation with polycystic ovary, and in few instances nonhyperandrogenic girls are misdiagnosed with polycystic ovaries entirely due to the fact that menstrual disturbances and PCO are probably associated with different conditions (Copp et al., 2017). The definition of PCOS follows strict standards for prognosis (Dewailly et al., 2014), as does the definition of hirsutism (Yildiz et al., 2012). Wolf et al. (2018) reported that a great distinction is gifting within the signs and symptoms throughout the diverse geographical places and among diverse races/ethnicities (Wolf et al., 2018). As current facts do stay limited, different research studies mentioned that there are distinctly great variations in the superiority of polycystic ovaries, its signs and symptoms, and cofactors (Chang et al., 2016).

1.7 CONCLUSION

PCOS is a multifaceted endocrine-metabolic disorder. It not only causes reproductive complications but also adversely affects the other systems in the body. Moreover, its symptoms are very diverse that have created main issues in finding the treatment for PCOS. Various therapeutic strategies are available in the market but they are not effective to cure this disease at the root level. Therefore, there is a need to dig out the actual molecular mechanism for the pathogenesis of this disorder.

BIBLIOGRAPHY

Akhter, S., Rutherford, S., Kumkum, F.A., Bromwich, D., Anwar, I., Rahman, A. and Chu, C., 2017. Work, gender roles, and health: neglected mental health issues among female workers in the ready-made garment industry in Bangladesh. *International Journal of Women's Health*, 9, p. 571.

Amato, M.C., Galluzzo, A., Finocchiaro, S., Criscimanna, A. and Giordano, C., 2008. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. *Clinical Endocrinology*, *69*(1), pp. 52–60.

Anderson, R.A., McLaughlin, M., Wallace, W.H.B., Albertini, D.F. and Telfer, E.E., 2014. The immature human ovary shows loss of abnormal follicles and increasing follicle developmental competence through childhood and adolescence. *Human Reproduction*, *29*(1), pp. 97–106.

Ansong, E., Arhin, S.K., Cai, Y., Xu, X. and Wu, X., 2019. Menstrual characteristics, disorders and associated risk factors among female international students in Zhejiang Province, China: a cross-sectional survey. *BMC Women's Health*, *19*(1), pp. 1–10.

Asunción, M., Calvo, R.M., San Millán, J.L., Sancho, J., Avila, S. and Escobar-Morreale, H.F., 2000. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. *The Journal of Clinical Endocrinology & Metabolism*, *85*(7), pp. 2434–2438.

Azziz, R. and Adashi, E.Y., 2016. Stein and Leventhal: 80 years on. *American Journal of Obstetrics and Gynecology*, *214*(2), pp. 247.e1–e11.

Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H.F., Futterweit, W., Janssen, O.E., Legro, R.S., Norman, R.J., Taylor, A.E. and Witchel, S.F., 2006. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. *The Journal of Clinical Endocrinology & Metabolism*, *91*(11), pp. 4237–4245.

Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H.F., Futterweit, W., Janssen, O.E., Legro, R.S., Norman, R.J., Taylor, A.E. and Witchel, S.F., 2009. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertility and Sterility*, *91*(2), pp. 456–488.

Azziz, R., Marin, C., Hoq, L., Badamgarav, E. and Song, P., 2005. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. *The Journal of Clinical Endocrinology & Metabolism*, *90*(8), pp. 4650–4658.

Azziz, R., Sanchez, L.A., Knochenhauer, E.S., Moran, C., Lazenby, J., Stephens, K.C., Taylor, K. and Boots, L.R., 2004. Androgen excess in women: experience with over 1000 consecutive patients. *The Journal of Clinical Endocrinology & Metabolism*, *89*(2), pp. 453–462.

Baillargeon, J.P., Iuorno, M.J. and Nestler, J.E., 2003. Insulin sensitizers for polycystic ovary syndrome. *Clinical Obstetrics and Gynecology*, *46*(2), pp. 325–340.

Bajaj, S., Jawad, F., Islam, N., Mahtab, H., Bhattarai, J., Shrestha, D., Wijeyaratne, C., Muthukuda, D.T., Widanage, N.W., Aye, T.T. and Aung, M.W., 2013. South Asian women with diabetes: psychosocial challenges and management: consensus statement. *Indian Journal of Endocrinology and Metabolism*, *17*(4), p. 548.

Basheer, M., Rai, S., Ghosh, H. and Hajam, Y.A., 2018. Protective role of seed extract of Tephrosia purpurea in letrozole induced polycystic ovary syndrome in wistar rats. *Journal of Biological Sciences*, *18*(8), pp. 458–467.

Bhattacharya, S.M. and Jha, A., 2011. Prevalence and risk of metabolic syndrome in adolescent Indian girls with polycystic ovary syndrome using the 2009 'joint interim criteria'. *Journal of Obstetrics and Gynaecology Research*, *37*(10), pp. 1303–1307.

Bird, S.T., Hartzema, A.G., Brophy, J.M., Etminan, M. and Delaney, J.A., 2013. Risk of venous thromboembolism in women with polycystic ovary syndrome: a populationbased matched cohort analysis. *Canadian Medical Association Journal*, *185*(2), pp. 115–120.

Boyle, J. and Teede, H.J., 2012. Polycystic ovary syndrome: an update. *Australian Family Physician*, *41*(10), pp. 752–756.

Broekmans, F.J., Knauff, E.A.H., Valkenburg, O., Laven, J.S., Eijkemans, M.J. and Fauser, B.C.J.M., 2006. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. *BJOG: An International Journal of Obstetrics & Gynaecology*, *113*(10), pp. 1210–1217.

Carlsson, I.B., Scott, J.E., Visser, J.A., Ritvos, O., Themmen, A.P.N. and Hovatta, O., 2006. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. *Human Reproduction*, *21*(9), pp. 2223–2227.

Chan, J.L., Kar, S., Vanky, E., Morin-Papunen, L., Piltonen, T., Puurunen, J., Tapanainen, J.S., Maciel, G.A.R., Hayashida, S.A.Y., Soares Jr, J.M. and Baracat, E.C., 2017. Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study. *American Journal of Obstetrics and Gynecology*, *217*(2), pp. 189.e1–e8.

Chang, A.Y., Oshiro, J., Ayers, C. and Auchus, R.J., 2016. Influence of race/ethnicity on cardiovascular risk factors in polycystic ovary syndrome, the Dallas Heart Study. *Clinical Endocrinology*, *85*(1), pp. 92–99.

Chung, E.K., Nurmohamed, L., Mathew, L., Elo, I.T., Coyne, J.C. and Culhane, J.F., 2010. Risky health behaviors among mothers-to-be: the impact of adverse childhood experiences. *Academic Pediatrics*, *10*(4), pp. 245–251.

Copp, T., Jansen, J., Doust, J., Mol, B.W., Dokras, A. and McCaffery, K., 2017. Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome? *British Medical Journal*, 358. https://doi.org/10.1136/bmj.j3694

Cuhaci, N., Polat, S.B., Evranos, B., Ersoy, R. and Cakir, B., 2014. Gynecomastia: clinical evaluation and management. *Indian Journal of Endocrinology and Metabolism*, *18*(2), p. 150.

Dai, J.B., Wang, Z.X. and Qiao, Z.D., 2015. The hazardous effects of tobacco smoking on male fertility. *Asian Journal of Andrology*, *17*(6), p. 954.

Davis, S.R., Knight, S., White, V., Claridge, C., Davis, B.J. and Bell, R., 2002. Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. *Gynecological Endocrinology*, *16*(6), pp. 443–446.

De Coster, S. and Van Larebeke, N., 2012. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. *Journal of Environmental and Public Health*. https://doi.org/10.1155/2012/713696

Detti, L., Jeffries-Boyd, H.E., Williams, L.J., Diamond, M.P. and Uhlmann, R.A., 2015. Fertility biomarkers to estimate metabolic risks in women with polycystic ovary syndrome. *Journal of Assisted Reproduction and Genetics*, *32*(12), pp. 1749–1756.

Dewailly, D., Lujan, M.E., Carmina, E., Cedars, M.I., Laven, J., Norman, R.J. and Escobar-Morreale, H.F., 2014. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. *Human Reproduction Update*, *20*(3), pp. 334–352.

Diamanti-Kandarakis, E. and Dunaif, A., 2012. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocrine Reviews*, *33*(6), pp. 981–1030.

Diamanti-Kandarakis, E., Piperi, C., Argyrakopoulou, G., Spina, J., Papanastasiou, L., Bergiele, A. and Panidis, D., 2006. Polycystic ovary syndrome: the influence of environmental and genetic factors. *Hormones*, *5*(1), p. 17.

Ding, T., Hardiman, P.J., Petersen, I., Wang, F.F., Qu, F. and Baio, G., 2017. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. *Oncotarget*, *8*(56), p. 96351.

Dumesic, D.A., Oberfield, S.E., Stener-Victorin, E., Marshall, J.C., Laven, J.S. and Legro, R.S., 2015. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. *Endocrine Reviews*, *36*(5), pp. 487–525.

Dumont, A., Robin, G. and Dewailly, D., 2018. Anti-Müllerian hormone in the pathophysiology and diagnosis of polycystic ovarian syndrome. *Current Opinion in Endocrinology, Diabetes and Obesity*, *25*(6), pp. 377–384.

Dunstan, D.W., Zimmet, P.Z., Welborn, T.A., De Courten, M.P., Cameron, A.J., Sicree, R.A., Dwyer, T., Colagiuri, S., Jolley, D., Knuiman, M. and Atkins, R., 2002. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. *Diabetes Care*, *25*(5), pp. 829–834.

Fathalla, M.F., 1997. *From Obstetrics and Gynaecology to Women's Health: The Road Ahead.* Nashville, TN: Parthenon Publishing.

Fauser, B.C., Tarlatzis, B.C., Rebar, R.W., Legro, R.S., Balen, A.H., Lobo, R., Carmina, E., Chang, J., Yildiz, B.O., Laven, J.S. and Boivin, J., 2012. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertility and Sterility*, *97*(1), pp. 28–38.

Fearnley, E.J., Marquart, L., Spurdle, A.B., Weinstein, P. and Webb, P.M., 2010. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case–control study. *Cancer Causes & Control*, *21*(12), pp. 2303–2308.

Franks, S., 1995. Polycystic ovary syndrome. *New England Journal of Medicine*, *333*(13), pp. 853–861.

Franks, S. and Hardy, K., 2018. Androgen action in the ovary. *Frontiers in Endocrinology*, *9*, p. 452.

Futterweit, W., 1999. Polycystic ovary syndrome: clinical perspectives and management. *Obstetrical & Gynecological Survey*, *54*(6), pp. 403–413.

Ganie, M.A., Vasudevan, V., Wani, I.A., Baba, M.S., Arif, T. and Rashid, A., 2019. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. *The Indian Journal of Medical Research*, *150*(4), p. 333.

Garad, R., Teede, H.J. and Moran, L., 2011. An evidence-based guideline for Polycystic Ovary Syndrome. *The Australian Nursing Journal: ANJ*, *19*(4), pp. 30–33.

Gaytan, F., Morales, C., Leon, S., Garcia-Galiano, D., Roa, J. and Tena-Sempere, M., 2015. Crowding and follicular fate: spatial determinants of follicular reserve and activation of follicular growth in the mammalian ovary. *PLoS One*, *10*(12), p. 0144099.

Gill, H., Tiwari, P. and Dabadghao, P., 2012. Prevalence of polycystic ovary syndrome in young women from North India: a community-based study. *Indian Journal of Endocrinology and Metabolism*, *16*(Suppl 2), p. S389.

Gleicher, N., Weghofer, A. and Barad, D.H., 2011. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? *Reproductive Biology and Endocrinology*, *9*(1), pp. 1–12.

Goodarzi, M.O. and Azziz, R., 2006. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. *Best Practice & Research Clinical Endocrinology & Metabolism*, *20*(2), pp. 193–205.

Goodarzi, M.O., Quiñones, M.J., Azziz, R., Rotter, J.I., Hsueh, W.A. and Yang, H., 2005. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. *Fertility and Sterility*, *84*(3), pp. 766–769.

Hart, R. and Doherty, D.A., 2015. The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. *The Journal of Clinical Endocrinology & Metabolism*, *100*(3), pp. 911–919.

Hart, R., Doherty, D.A., Mori, T., Huang, R.C., Norman, R.J., Franks, S., Sloboda, D., Beilin, L. and Hickey, M., 2011. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. *Fertility and Sterility*, *95*(7), pp. 2347–2353.

Hidaka, T., Yonezawa, R. and Saito, S., 2013. Kami-shoyo-san, Kampo (Japanese traditional medicine), is effective for climacteric syndrome, especially in hormone-replacement-therapy-resistant patients who strongly complain of psychological symptoms. *Journal of Obstetrics and Gynaecology Research*, *39*(1), pp. 223–228.

Homburg, R., 2009. Androgen circle of polycystic ovary syndrome. *Human Reproduction*, *24*(7), pp. 1548–1555.

Huang, Z. and Yong, E.L., 2016. Ethnic differences: is there an Asian phenotype for polycystic ovarian syndrome? *Best Practice & Research Clinical Obstetrics & Gynaecology*, *37*, pp. 46–55.

Jeppesen, J.V., Kristensen, S.G., Nielsen, M.E., Humaidan, P., Dal Canto, M., Fadini, R., Schmidt, K.T., Ernst, E. and Yding Andersen, C., 2012. LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. *The Journal of Clinical Endocrinology & Metabolism*, *97*(8), pp. 1524–1531.

Johnson, T.R.B., Kaplan, L.K., Ouyang, P., Rizza, R.A. and National Institutes of Health, 2012. *Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome*. Bethesda, MD: National Institutes of Health.

Jones, G.L., Hall, J.M., Balen, A.H. and Ledger, W.L., 2008. Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. *Human Reproduction Update*, *14*(1), pp. 15–25.

Joshi, B., Mukherjee, S., Patil, A., Purandare, A., Chauhan, S. and Vaidya, R., 2014. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. *Indian Journal of Endocrinology and Metabolism*, *18*(3), p. 317.

Kaczmarek, C., Haller, D.M. and Yaron, M., 2016. Health-related quality of life in adolescents and young adults with polycystic ovary syndrome: a systematic review. *Journal of Pediatric and Adolescent Gynecology*, *29*(6), pp. 551–557.

Kaewnin, J., Vallibhakara, O., Arj-Ong Vallibhakara, S., Wattanakrai, P., Butsripoom, B., Somsook, E., Hongsanguansri, S. and Sophonsritsuk, A., 2018. Prevalence of polycystic ovary syndrome in Thai University adolescents. *Gynecological Endocrinology*, *34*(6), pp. 476–480.

Kauffman, R.P., Baker, V.M., DiMarino, P., Gimpel, T. and Castracane, V.D., 2002. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. *American Journal of Obstetrics and Gynecology*, *187*(5), pp. 1362–1369.

Kaur, J., Patil, M., Kar, S., Jirge, P.R. and Mahajan, N., 2019. Distribution of anthropometric, clinical, and metabolic profiles of women with polycystic ovary syndrome across the four regions of India. *The Onco Fertility Journal*, *2*(1), p. 20.

Klein, D.A. and Poth, M.A., 2013. Amenorrhea: an approach to diagnosis and management. *American Family Physician*, *87*(11), pp. 781–788.

Knochenhauer, E.S., Key, T.J., Kahsar-Miller, M., Waggoner, W., Boots, L.R. and Azziz, R., 1998. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *The Journal of Clinical Endocrinology & Metabolism*, *83*(9), pp. 3078–3082.

Konieczna, A., Rutkowska, A. and Rachon, D., 2015. Health risk of exposure to Bisphenol A (BPA). *RocznikiPaństwowegoZakładuHigieny*, *66*(1), pp. 5–11.

Kristensen, S.G., Liu, Q., Mamsen, L.S., Greve, T., Pors, S.E., Bjørn, A.B., Ernst, E., Macklon, K.T. and Andersen, C.Y., 2018. A simple method to quantify follicle survival in cryopreserved human ovarian tissue. *Human Reproduction*, *33*(12), pp. 2276–2284.

Kumarapeli, V., Seneviratne, R.D.A., Wijeyaratne, C.N., Yapa, R.M.S.C. and Dodampahala, S.H., 2008. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semiurban population in Sri Lanka. *American Journal of Epidemiology*, *168*(3), pp. 321–328.

Laird, M., Thomson, K., Fenwick, M., Mora, J., Franks, S. and Hardy, K., 2017. Androgen stimulates growth of mouse preantral follicles in vitro: interaction with follicle-stimulating hormone and with growth factors of the TGF β superfamily. *Endocrinology*, *158*(4), pp. 920–935.

Lauritsen, M.P., Bentzen, J.G., Pinborg, A., Loft, A., Forman, J.L., Thuesen, L.L., Cohen, A., Hougaard, D.M. and Nyboe Andersen, A., 2014. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone. *Human Reproduction*, *29*(4), pp. 791–801.

Lee, H., Oh, J.Y., Sung, Y.A., Chung, H. and Cho, W.Y., 2009. The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. *Endocrine*, *36*(2), pp. 326–332.

Li, R., Zhang, Q., Yang, D., Li, S., Lu, S., Wu, X., Wei, Z., Song, X., Wang, X., Fu, S. and Lin, J., 2013. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. *Human Reproduction*, *28*(9), pp. 2562–2569.

Lim, S.S., Norman, R.J., Davies, M.J. and Moran, L.J., 2013. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. *Obesity Reviews*, *14*(2), pp. 95–109.

Mani, H., Davies, M.J., Bodicoat, D.H., Levy, M.J., Gray, L.J., Howlett, T.A. and Khunti, K., 2015. Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. *Clinical Endocrinology*, *83*(4), pp. 542–554.

March, W.A., Moore, V.M., Willson, K.J., Phillips, D.I., Norman, R.J. and Davies, M.J., 2010. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Human Reproduction*, *25*(2), pp. 544–551.

Marques, P., Skorupskaite, K., George, J.T. and Anderson, R.A., 2018. Physiology of GNRH and gonadotropin secretion. In Endotext, edited by Feingold, K.R., Anawalt, B., and Blackman, M.R. South Dartmouth, MA: MDText Publisher.

Mehrabian, F. and Eessaei, F., 2012. The laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome; a randomized controlled trial. *Journal of Pakistan Medical Association*, *62*(2), pp. S42–S44.

Meurer, L.N., Kroll, A.P. and Jamieson, B., 2006. What is the best way to diagnose polycystic ovarian syndrome? *Journal of Family Practice*, *55*(4), pp. 351–354.

Moran, C., Tena, G., Moran, S., Ruiz, P., Reyna, R. and Duque, X., 2010. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. *Gynecologic and Obstetric Investigation*, *69*(4), pp. 274–280.

Nidhi, R., Padmalatha, V., Nagarathna, R. and Amritanshu, R., 2011. Prevalence of polycystic ovarian syndrome in Indian adolescents. *Journal of Pediatric and Adolescent Gynecology*, *24*(4), pp. 223–227.

Noonan, G.O., Ackerman, L.K. and Begley, T.H., 2011. Concentration of bisphenol A in highly consumed canned foods on the US market. *Journal of Agricultural and Food Chemistry*, *59*(13), pp. 7178–7185.

Ogden, C.L., Carroll, M.D., Kit, B.K. and Flegal, K.M., 2012. Prevalence of obesity among adults: United States. *NCHS Data Brief*, *2013*(131), pp. 1–8.

Okoroh, E.M., Hooper, W.C., Atrash, H.K., Yusuf, H.R. and Boulet, S.L., 2012a. Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003–2008. *American Journal of Obstetrics and Gynecology*, *207*(4), pp. 1–7. https://doi.org/10.1016/j.ajog.2012.07.023

Okoroh, E.M., Hooper, W.C., Atrash, H.K., Yusuf, H.R. and Boulet, S.L., 2012b. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003–2008. *American Journal of Obstetrics and Gynecology*, 207, pp. 377.e1–e8.

Özen, S. and Darcan, Ş., 2011. Effects of environmental endocrine disruptors on pubertal development. *Journal of Clinical Research in Pediatric Endocrinology*, *3*(1), p. 1.

Pfieffer, M.L., 2019. Polycystic ovary syndrome: diagnosis and management. *Journal for Nurse Practitioners*, 44, pp. 30–35.

Pulman, A., 2010. A patient centred framework for improving LTC quality of life through Web 2.0 technology. *Health Informatics Journal*, *16*(1), pp. 15–23.

Rai, S., Basheer, M., Ghosh, H., Acharya, D. and Hajam, Y.A., 2015. Melatonin attenuates free radical load and reverses histologic architect and hormone profile alteration in female rat: an in vivo study of pathogenesis of letrozole induced poly cystic ovary. *Clinical & Cellular Immunology*, *6*, pp. 1–8.

Raju, G.A.R., Chavan, R., Deenadayal, M., Gunasheela, D., Gutgutia, R., Haripriya, G., Govindarajan, M., Patel, N.H. and Patki, A.S., 2013. Luteinizing hormone and follicle stimulating hormone synergy: a review of role in controlled ovarian hyper-stimulation. *Journal of Human Reproductive Sciences*, *6*(4), p. 227.

Rani, R., Hajam, Y.A., Kumar, R., Bhat, R.A., Rai, S. and Rather, M.A., 2022. A landscape analysis of the potential role of polyphenols for the treatment of Polycystic Ovarian Syndrome (PCOS). *Phytomedicine Plus*, *2*(1), p. 100161.

Razak, F., Anand, S., Vuksan, V., Davis, B., Jacobs, R., Teo, K.K. and Yusuf, S., 2005. Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. *International Journal of Obesity*, *29*(6), pp. 656–667.

Rosenfield, R.L. and Ehrmann, D.A., 2016. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. *Endocrine Reviews*, *37*(5), pp. 467–520.

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility*, *81*(1), pp. 19–25.

Saadia, Z., 2020. Follicle stimulating hormone (LH: FSH) ratio in polycystic ovary syndrome (PCOS)-obese vs. non-obese women. *Medical Archives*, *74*(4), p. 289.

Sakamoto, M., Nishimura, R., Irako, T., Tsujino, D., Ando, K. and Utsunomiya, K., 2012. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). *Cardiovascular Diabetology*, *11*(1), pp. 1–7.

Seifert, S.M., Schaechter, J.L., Hershorin, E.R. and Lipshultz, S.E., 2011. Health effects of energy drinks on children, adolescents, and young adults. *Pediatrics*, *127*(3), pp. 511–528.

Sen, A. and Hammes, S.R., 2010. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. *Molecular Endocrinology*, *24*(7), pp. 1393–1403.

Shannon, M. and Wang, Y., 2012. Polycystic ovary syndrome: a common but often unrecognized condition. *Journal of Midwifery & Women's Health*, *57*(3), pp. 221–230.

Sirmans, S.M. and Pate, K.A., 2014. Epidemiology, diagnosis, and management of polycystic ovary syndrome. *Clinical Epidemiology*, *6*, p. 1.

Stepto, N.K., Cassar, S., Joham, A.E., Hutchison, S.K., Harrison, C.L., Goldstein, R.F. and Teede, H.J., 2013. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemichyperinsulaemic clamp. *Human Reproduction*, *28* (3), pp. 777–784.

Stracquadanio, M. and Ciotta, L., 2015. *Metabolic Aspects of PCOS*. Heidelberg, NY: Springer.

Tan, B.K., Adya, R., Farhatullah, S., Lewandowski, K.C., O'Hare, P., Lehnert, H. and Randeva, H.S., 2008. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. *Diabetes*, *57*(4), pp. 801–808.

Teede, H., Deeks, A. and Moran, L., 2010. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BioMed Central Medicine*, *8*(1), pp. 1–10.

Teede, H.J., Misso, M.L., Deeks, A.A., Moran, L.J., Stuckey, B.G., Wong, J.L., Norman, R.J. and Costello, M.F., 2011. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. *The Medical Journal of Australia*, *195*(6), p. S65.

Tsutsumi, R. and Webster, N.J., 2009. GnRH pulsatility, the pituitary response and reproductive dysfunction. *Endocrine Journal*, *56*(6), pp. 729–737.

Victor, V.M., Apostolova, N., Herance, R., Hernandez-Mijares, A. and Rocha, M., 2009. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. *Current Medicinal Chemistry*, *16*(35), pp. 4654–4667.

Vink, J.M., Sadrzadeh, S., Lambalk C.B., and Boomsma, D.I. Heritability of polycystic ovary syndrome in a Dutch twin-family study. Journal of Clinical Endocrinology Metabolism, 91(6), pp. 2100–2104.

Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M. and Wu, T., 2009. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. *Cell*, *138*(2), pp. 245–256.

Wedin, W.K., Diaz-Gimenez, L. and Convit, A.J., 2012. Prediction of insulin resistance with anthropometric measures: lessons from a large adolescent population. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, *5*, p. 219.

Wijeyaratne, C.N., Balen, A.H., Barth, J.H. and Belchetz, P.E., 2002. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? *Clinical endocrinology*, *57*(3), pp. 343–350.

Wilfley, D., Berkowitz, R., Goebel-Fabbri, A., Hirst, K., Ievers-Landis, C., Lipman, T.H., Marcus, M., Ng, D., Pham, T., Saletsky, R. and Schanuel, J., 2011. Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study. *Diabetes Care*, *34*(4), pp. 858–860.

Williams, S., Sheffield, D. and Knibb, R.C., 2015. 'Everything's from the inside out with PCOS': exploring women's experiences of living with polycystic ovary syndrome and co-morbidities through Skype™ interviews. *Health Psychology Open*, *2*(2), p. 2055102915603051.

Winter, E., Wang, J., Davies, M.J. and Norman, R., 2002. Early pregnancy loss following assisted reproductive technology treatment. *Human Reproduction*, *17*(12), pp. 3220–3223.

Wolf, W.M., Wattick, R.A., Kinkade, O.N. and Olfert, M.D., 2018. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. *International Journal of Environmental Research and Public Health*, *15*(11), p. 2589.

Xu, J., Bishop, C.V., Lawson, M.S., Park, B.S. and Xu, F., 2016. Anti-Müllerian hormone promotes pre-antral follicle growth, but inhibits antral follicle maturation and dominant follicle selection in primates. *Human Reproduction*, *31*(7), pp. 1522–1530.

Yang, Y., Ok, Y.S., Kim, K.H., Kwon, E.E. and Tsang, Y.F., 2017. Occurrences and removal of pharmaceuticals and personal care products (PPCPs) in drinking water and water/sewage treatment plants: a review. *Science of the Total Environment*, *596*, pp. 303–320.

Yildiz, B.O., Bozdag, G., Yapici, Z., Esinler, I. and Yarali, H., 2012. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. *Human Reproduction*, *27*(10), pp. 3067–3073.

Young, J.M. and McNeilly, A.S., 2010. Theca: the forgotten cell of the ovarian follicle. *Reproduction*, *140*(4), p. 489.

Zawadeski, J.K. and Dunaif, A., 1992. Diagnostic criteria for polycystic ovary syndrome: Towards a more rational approach. In *Polycystic Ovary Syndrome,* edited by Dunaif, A., Givens, J.R. and Haseltine, F. Boston, MA: Blackwell Scientific, pp. 377–384.

Zhao, Y. and Qiao, J., 2013. Ethnic differences in the phenotypic expression of polycystic ovary syndrome. *Steroids*, *78*(8), pp. 755–760.

Zuo, T., Zhu, M. and Xu, W., 2016. Roles of oxidative stress in polycystic ovary syndrome and cancers. *Oxidative Medicine and Cellular Longevity*. https://doi.org/10.1155/2016/8589318